Extended Data Fig. 3: Progression-free and overall survival estimates stratified by adjuvant immunotherapy.

(a) Patients who received adjuvant immunotherapy in Arm A (n = 8) had a trend toward longer PFS compared to patients who did not (n = 4), with a median PFS of 15.92 versus 5.92 months, respectively (log-rank test, p = 0.029; HR = 0.20, 95% CI: 0.038–0.99). (b) Patients who received adjuvant immunotherapy in Arm B (n = 6) had a trend toward longer PFS when compared to patients who did not (n = 5), with a median PFS of 21.88 versus 17.68 months, respectively (log-rank test, p = 0.01; HR not estimable). (c) Patients who received adjuvant immunotherapy in Arm A (n = 8) had no clear difference in OS compared to patients who did not (n = 4), with a median OS of 21.60 versus 12.85 months, respectively (log-rank test, p = 0.1; HR = 0.31, 95% CI: 0.067 – 1.39). (d) Patients who received adjuvant immunotherapy in Arm B (n = 6) had a trend toward longer OS when compared to patients who did not (n = 5), with a median OS of 28.85 versus 18.79 months, respectively (log-rank test, p = 0.01; HR not estimable). Survival intervals for these analyses were computed with surgery date as the landmark time. For the survival analyses where hazards ratios were not estimable, this was driven by the fact that all PFS and OS events occurred first in the subset of patients who did not receive adjuvant immunotherapy before any events occurred in those who received adjuvant immunotherapy. Abbreviations: PFS, progression-free survival; OS, overall survival; HR, hazard ratio.